AI-powered search

On-Demand CME Videos

Chronic Spontaneous Urticaria: Understanding the Burden, Diagnosis and Treatment Journey: Online CME Activity

About

Chronic Spontaneous Urticaria: Understanding the Burden, Diagnosis and Treatment Journey: Online CME Activity

This activity is supported by educational grants from Genentech, a member of the Roche Group, Novartis Pharmaceuticals Corporation, and Sanofi and Regeneron Pharmaceuticals, Inc.

Availability

In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

March 28, 2024

Expiration Date:

April 1, 2025

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Describe the burden of CSU and potential impacts to patient quality of life

  • Discuss strategies for optimizing the diagnosis of CSU

  • Define the role of targeted therapies for the treatment and management of CSU

  • Identify approaches for the delivery of optimal patient-centered care in CSU

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
April
April Armstrong, MD, MPH

Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Aaron
Aaron Farberg, MD

Bare Dermatology
Baylor Scott & White Health System
Dallas, TX

Dawn
Dawn Merritt, DO

Dermatology Residency Program Director
OhioHealth Riverside Hospital
Columbus, OH

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

Disclosures are as follows:

April W. Armstrong, MD, MPH

Advisory Board/Consultant: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer

Grant/Research Support: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer

Aaron S. Farberg, MD

Speakers’ Bureau or Honoraria: Novartis, Sanofi Regeneron, SUN Pharma, Galderma, Castle Biosciences, Janssen, Ortho Dermatologics, Pfizer 

Dawn L. Merritt, DO

Consultant: Abbvie, Arcutis, BMS, Dermavant, Lilly, Novartis, UCB
Speaker's Bureau or Honoraria: Abbvie, Amgen, BMS, Dermavent, LEO, Lilly, Pfizer

The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved